Portage Biotech (NASDAQ:ALP) Stock: Insider Fiorenzo Villani Buys 10,000 Shares

Portage Biotech Inc. (NASDAQ:ALP) insider Fiorenzo Villani purchased 10,000 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The stock was bought at an average price of $4.40 per share, with a total value of $44,000.00. Following the completion of the transaction, the insider owned 48,886 shares of the company’s stock, valued at $215,098.40. The trade was a 25.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Fiorenzo Villani also recently made the following trade(s):

• On Wednesday, September 16th, Fiorenzo Villani acquired 4,265 shares of Portage Biotech stock. The shares were purchased at an average price of $4.05 per share, for a total transaction of $17,273.25.
• On Tuesday, September 15th, Fiorenzo Villani bought 7,900 shares of Portage Biotech stock. The stock was purchased at an average cost of $4.15 per share, for a total transaction of $32,785.00.
• On Tuesday, September 15th, Fiorenzo Villani bought 10,382 shares of Portage Biotech stock. The stock was purchased at an average price of $4.07 per share, with a total value of $42,254.74.
• On Monday, September 14th, Fiorenzo Villani purchased 2,000 shares of Portage Biotech stock. The shares were purchased at an average cost of $4.16 per share, with a total value of $8,320.00.
• On Wednesday, September 9th, Fiorenzo Villani purchased 7,000 shares of Portage Biotech stock. The shares were purchased at an average price of $5.07 per share, for a total transaction of $35,490.00.

Portage Biotech Stock Performance

Shares of NASDAQ:ALP opened at $5.61 on Friday. The company has a current ratio of 0.31, a quick ratio of 0.31 and a debt-to-equity ratio of 0.01. Portage Biotech Inc. has a 12 month low of $3.20 and a 12 month high of $690.00. The company has a market capitalization of $8.70 million, a price-to-earnings ratio of -0.01 and a beta of 0.54. The firm’s 50-day moving average is $8.60 and its 200 day moving average is $13.86.

Portage Biotech (NASDAQ:ALP) last announced its earnings results on Thursday, July 16th. The company reported $23.75 earnings per share (EPS) for the quarter. The business had revenue of $0.05 million for the quarter. Research analysts predict that Portage Biotech Inc. will post -14 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Zacks Research upgraded Portage Biotech to a “hold” rating in a research note on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Portage Biotech in a research note on Friday, July 24th. HC Wainwright started coverage on shares of Portage Biotech in a report on Monday, August 17th. They issued a “neutral” rating and a $12.50 price target on the stock. Finally, Wall Street Zen raised shares of Portage Biotech to a “hold” rating in a research note on Saturday, September 12th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Portage Biotech presently has a consensus rating of “Reduce” and an average price target of $12.50.

Portage Biotech Company Profile

Portage Biotech Inc is a clinical-stage biotechnology company focused on developing immuno-oncology treatments designed to stimulate the immune system to target and eliminate cancer cells. Its research has centered on therapies involving invariant natural killer T (iNKT) cells, a specialized immune-cell population that may help generate targeted antitumor responses.

The company’s pipeline has included investigational therapies intended for use in solid tumors, including approaches that combine immune-cell activation with mechanisms designed to improve the tumor microenvironment and enhance treatment response.